{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:19:29Z","timestamp":1787570369963,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00120-026-02890-9","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:38:37Z","timestamp":1785328717000},"page":"950-958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["K\u00fcnstliche Intelligenz bei der Betreuung geriatrischer Patienten\u00a0\u2013 mehr Fluch oder mehr Segen?","Artificial intelligence in the care of geriatric patients\u2014more of a\u00a0curse or more of a\u00a0blessing?"],"prefix":"10.1007","volume":"65","author":[{"given":"Andreas","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fr\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Umbehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2890_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01276-6","volume":"10","author":"J Li","year":"2026","unstructured":"Li\u00a0J, Zhang\u00a0L, Yu\u00a0Z, Bao\u00a0Z, Li\u00a0D, Wang\u00a0L (2026) The impact of AI on modern oncology from early detection to personalized cancer treatment. NPJ Precis Oncol 10:69","journal-title":"NPJ Precis Oncol"},{"key":"2890_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1532-5415.1999.tb05204.x","volume":"47","author":"J McCusker","year":"1999","unstructured":"McCusker\u00a0J, Bellavance\u00a0F, Cardin\u00a0S, Trepanier\u00a0S, Verdon\u00a0J, Ardman\u00a0O (1999) Detection of older people at increased risk of adverse health outcomes after an emergency visit: the ISAR screening tool. J\u00a0Am Geriatr Soc 47:1229\u20131237","journal-title":"J Am Geriatr Soc"},{"key":"2890_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000358825","volume":"60","author":"K Singler","year":"2014","unstructured":"Singler\u00a0K, Heppner\u00a0HJ, Skutetzky\u00a0A, Sieber\u00a0C, Christ\u00a0M, Thiem\u00a0U (2014) Predictive validity of the identification of seniors at risk screening tool in a German emergency department setting. Gerontology 60:413\u2013419","journal-title":"Gerontology"},{"key":"2890_CR4","unstructured":"Wiedemann A, Puttmann J, Heppner H. [The ISAR-positive patient in urology]. Aktuelle Urol 2018."},{"key":"2890_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.purol.2017.10.006","volume":"28","author":"I Cholley","year":"2018","unstructured":"Cholley\u00a0I, Correas\u00a0JM, Masson-Lecomte\u00a0A et\u00a0al (2018) Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75. Prog Urol 28:55\u201361","journal-title":"Prog Urol"},{"key":"2890_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/01.NAJ.0000292197.76076.e1","volume":"107","author":"T Fulmer","year":"2007","unstructured":"Fulmer\u00a0T (2007) How to try this: Fulmer\u00a0SPICES. Am J Nurs 107:40\u201348","journal-title":"Am J Nurs"},{"key":"2890_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/a-0875-0648","volume":"51","author":"Y Rassam","year":"2020","unstructured":"Rassam\u00a0Y, Schindler\u00a0A, Willschrei\u00a0P, Horstmann\u00a0M (2020) The G8 questionnaire as a\u00a0geriatric screening tool in urooncology. Aktuelle Urol 51:36\u201341","journal-title":"Aktuelle Urol"},{"key":"2890_CR8","first-page":"61","volume":"14","author":"FI Mahoney","year":"1965","unstructured":"Mahoney\u00a0FI, Barthel\u00a0DW (1965) Functional Evaluation: The Barthel\u00a0Index. Md State Med J 14:61\u201365","journal-title":"Md State Med J"},{"key":"2890_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.20041","volume":"23","author":"K Avery","year":"2004","unstructured":"Avery\u00a0K, Donovan\u00a0J, Peters\u00a0TJ, Shaw\u00a0C, Gotoh\u00a0M, Abrams\u00a0P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322\u2013330","journal-title":"Neurourol Urodyn"},{"key":"2890_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1590\/S1677-55382004000200011","volume":"30","author":"P Rodrigues","year":"2004","unstructured":"Rodrigues\u00a0P, Meller\u00a0A, Campagnari\u00a0JC, Alcantara\u00a0D, D\u2019Imperio\u00a0M (2004) International Prostate Symptom Score--IPSS-AUA as discriminat scale in 400 male patients with lower urinary tract symptoms (LUTS). Int Braz J Urol 30:135\u2013141","journal-title":"Int Braz J Urol"},{"key":"2890_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein\u00a0MF, Folstein\u00a0SE, McHugh\u00a0PR (1975) \u201cMini-mental state\u201d. A\u00a0practical method for grading the cognitive state of patients for the clinician. J\u00a0Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"2890_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U","volume":"15","author":"KI Shulman","year":"2000","unstructured":"Shulman\u00a0KI (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548\u2013561","journal-title":"Int J Geriatr Psychiatry"},{"key":"2890_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/j.1532-5415.1993.tb07308.x","volume":"41","author":"YI Watson","year":"1993","unstructured":"Watson\u00a0YI, Arfken\u00a0CL, Birge\u00a0SJ (1993) Clock completion: an objective screening test for dementia. J\u00a0Am Geriatr Soc 41:1235\u20131240","journal-title":"J Am Geriatr Soc"},{"key":"2890_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ggi.13163","volume":"18","author":"T Tanaka","year":"2018","unstructured":"Tanaka\u00a0T, Takahashi\u00a0K, Akishita\u00a0M, Tsuji\u00a0T, Iijima\u00a0K (2018) \u201cYubi-wakka\u201d (finger-ring) test: A\u00a0practical self-screening method for sarcopenia, and a\u00a0predictor of disability and mortality among Japanese community-dwelling older adults. Geriatr Gerontol Int 18:224\u2013232","journal-title":"Geriatr Gerontol Int"},{"key":"2890_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo\u00a0D, Richardson\u00a0S (1991) The timed \u201cUp Go\u201d: a test of basic functional mobility for frail elderly persons. J\u00a0Am Geriatr Soc 39:142\u2013148","journal-title":"J Am Geriatr Soc"},{"key":"2890_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.gerinurse.2019.09.003","volume":"41","author":"HS Kang","year":"2020","unstructured":"Kang\u00a0HS, Makimoto\u00a0K, Konno\u00a0R, Koh\u00a0IS (2020) Review of outcome measures in PARO robot intervention studies for dementia care. Geriatr Nurs 41:207\u2013214","journal-title":"Geriatr Nurs"},{"key":"2890_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jamda.2017.10.008","volume":"19","author":"MC Mervin","year":"2018","unstructured":"Mervin\u00a0MC, Moyle\u00a0W, Jones\u00a0C et\u00a0al (2018) The Cost-Effectiveness of Using PARO, a Therapeutic Robotic Seal, to Reduce Agitation and Medication Use in Dementia: Findings from a Cluster-Randomized Controlled Trial. J\u00a0Am Med Dir Assoc 19:619\u2013622","journal-title":"J Am Med Dir Assoc"},{"key":"2890_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jamda.2020.01.014","volume":"21","author":"L Pu","year":"2020","unstructured":"Pu\u00a0L, Moyle\u00a0W, Jones\u00a0C, Todorovic\u00a0M (2020) The Effect of Using PARO for People Living With Dementia and Chronic Pain: A Pilot Randomized Controlled Trial. J\u00a0Am Med Dir Assoc 21:1079\u20131085","journal-title":"J Am Med Dir Assoc"},{"key":"2890_CR19","first-page":"65","volume":"326","author":"A Khan","year":"2025","unstructured":"Khan\u00a0A, Wahid\u00a0SR, Sattar\u00a0J, Khashayar\u00a0P (2025) Reactions and Engagement of Individuals with Dementia Toward Humanoid Assistive Robots: A Study Using the Pepper Robot. Stud Health Technol Inform 326:65\u201369","journal-title":"Stud Health Technol Inform"},{"key":"2890_CR20","first-page":"101","volume":"323","author":"AW Kushniruk","year":"2025","unstructured":"Kushniruk\u00a0AW, Nair\u00a0HS, Borycki\u00a0EM (2025) The Pepper Robot in Healthcare: A Scoping Review. Stud Health Technol Inform 323:101\u2013105","journal-title":"Stud Health Technol Inform"},{"key":"2890_CR21","unstructured":"Tully KH, Nguyen DD, Herzog P, et\u00a0al. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy. Eur Urol Oncol 2019."},{"key":"2890_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12672-018-0335-8","volume":"9","author":"Z Chen","year":"2018","unstructured":"Chen\u00a0Z, Deng\u00a0J, Yan\u00a0Y et\u00a0al (2018) Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome. Horm Cancer 9:278\u2013287","journal-title":"Horm Cancer"},{"key":"2890_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/EDE.0000000000000678","volume":"28","author":"BM Hicks","year":"2017","unstructured":"Hicks\u00a0BM, Klil-Drori\u00a0AJ, Yin\u00a0H, Campeau\u00a0L, Azoulay\u00a0L (2017) Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer. Epidemiology 28:712\u2013718","journal-title":"Epidemiology"},{"key":"2890_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21681805.2019.1570328","volume":"53","author":"MH Poulsen","year":"2019","unstructured":"Poulsen\u00a0MH, Frost\u00a0M, Abrahamsen\u00a0B, Gerke\u00a0O, Walter\u00a0S, Lund\u00a0L (2019) Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. Scand J Urol 53:34\u201339","journal-title":"Scand J Urol"},{"key":"2890_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1754-9485.12124","volume":"58","author":"D Chang","year":"2014","unstructured":"Chang\u00a0D, Joseph\u00a0DJ, Ebert\u00a0MA et\u00a0al (2014) Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J\u00a0Med Imaging Radiat Oncol 58:223\u2013228","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2890_CR26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.acuro.2015.01.004","volume":"39","author":"JI Monzo-Gardiner","year":"2015","unstructured":"Monzo-Gardiner\u00a0JI, Herranz-Amo\u00a0F (2015) Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy. Actas Urol Esp 39:518\u2013522","journal-title":"Actas Urol Esp"},{"key":"2890_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcph.1332","volume":"59","author":"HH Kao","year":"2019","unstructured":"Kao\u00a0HH, Kao\u00a0LT, Li\u00a0IH et\u00a0al (2019) Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study. J\u00a0Clin Pharmacol 59:335\u2013343","journal-title":"J Clin Pharmacol"},{"key":"2890_CR28","doi-asserted-by":"crossref","unstructured":"Margel D, Peer A, Ber Y, et\u00a0al. Cardiovascular Morbidity in a\u00a0Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J\u00a0Urol 2019:101097JU0000000000000384.","DOI":"10.1097\/JU.0000000000000384"},{"key":"2890_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11523-023-00959-5","volume":"18","author":"SCR Williams","year":"2023","unstructured":"Williams\u00a0SCR, Mazibuko\u00a0N, O\u2019Daly\u00a0O et\u00a0al (2023) Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial. Target Oncol 18:403\u2013413","journal-title":"Target Oncol"},{"key":"2890_CR30","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2025) S3-Leitlinie Prostatakarzinom, Langversion 8.1. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/. Zugegriffen: 10. Juni 2026"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02890-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:22:52Z","timestamp":1787566972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02890-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02890-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Wiedemann: Berater- bzw. Gutachtert\u00e4tigkeiten: Acticore; Astellas; Bayer Pharma; Dr. Pfleger; Merck; MIP Arzneimittel; Novartis. Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): Dr. Pfleger; Pfizer; MIP Arzneimittel; Bayer; Novartis. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Allergan; AMS Deutschland; Aristo; Astellas Pharma; Bayer Pharma; Besins Deutschland; Berlin-Chemie; Das Fortbildungskolleg; Jansen; Lilly Deutschland; Meda; Merck; MIP Arzneimittel; Novartis; Dr. Pfleger; Pierre Fabre; Pfizer Pharma. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: AMS Deutschland; Boston Scientific; Dr. Pfleger; Paul-Kuth-Stiftung der Deutschen Bank. Indirekte Interessen \u2013\u00a0Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie (aktuell Leitung Arbeitskreis geriatrische Urologie); Deutsche Gesellschaft f\u00fcr Geriatrie (aktuell Leitung Arbeitsgruppe Harinkontinenz); NRW-Gesellschaft f\u00fcr Urologie (gew\u00e4hlt zum Kongresspr\u00e4sidenten 2025); Deutsche Kontinenzgesellschaft (aktuell 1.\u00a0Vorsitzender); Institut f\u00fcr Geriatrische Pharmazie und interdisziplin\u00e4re Geriatrie e.\u202fV. A.\u00a0Manseck: Berater- bzw. Gutachtert\u00e4tigkeiten: Gerichtsgutachter; Gutachter Landes\u00e4rztekammer. Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): F\u00f6rderverein zur Unterst\u00fctzung Krebskranker in der Region Ingolstadt e.\u202fV. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Urologie Online-Veranstalter: DGU; UroWorxx, Veranstalter: Christine Gerner; Boston Scientific Medizintechnik GmbH. Autoren-\/oder Koautorenschaft:\n                      \n                      . Indirekte Interessen\u00a0\u2013 Mitgliedschaften: Generalsekret\u00e4r der bayerischen Urologenvereinigung; Schriftf\u00fchrer im Arbeitskreis Geriatrische Urologie der Deutschen Gesellschaft f\u00fcr Urologie; Schriftf\u00fchrer und Schatzmeister im Arbeitskreis Laparoskopie und roboterassistierte Chirurgie der Deutschen Gesellschaft f\u00fcr Urologie; Fachexperte Fa. OnkoZert; Mitglied im Ausschuss Zertifikatserteilung der Fa. OnkoZert; Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Kommission Prostatakrebszentren\/Peniskarzinom (PZ); Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Harnblasenkarzinomzentren (MB); Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Nierenzellkarzinomzentren (MN). J.\u00a0Stein: Berater- bzw. Gutachtert\u00e4tigkeiten: Gutachter f\u00fcr Schlichtungsstellen \u00c4KN und \u00c4KHH; Fa. Bayer, AAA\/Novartis. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Fa. Medac; Fa. Lilly. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firmen: Astellas, Boston Scientific, Dr. Pfleger, Medtronic, Medac, Sanofi, Lilly, Jenapharm, AMS, Janssen, Pfizer, Takeda, MSD, Gr\u00fcnenthal, AAA\/Novartis. Besitz von Gesch\u00e4ftsanteilen, Aktien, Fonds mit Beteiligung von Unternehmen der Gesundheitswissenschaft: Bristol-Myers Squibb. C.\u00a0Fiebig: Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Merck Healthcare Germany GmbH. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Deutsche Forschungsgemeinschaft (DFG). A.\u00a0Piotrowski: Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): Firma Bayer. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firma Pfleger. M.\u00a0Fr\u00f6hner und M.\u00a0Umbehr geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}